Skip to main content
Premium Trial:

Request an Annual Quote

Six New Members Join WIN Consortium

NEW YORK (GenomeWeb) – The Worldwide Innovative Networking Consortium in personalized cancer medicine today announced the approval of six new members.

The new members are Asan Medical Center in South Korea; Cambridge Cancer Center in the UK; Cancer Research UK; CEO Roundtable on Cancer, headquartered in Cary, NC; the Kimmel Cancer Center at Jefferson in Philadelphia; and Memorial Sloan Kettering Cancer Center in New York.

The WIN Consortium now has 39 member organizations who share a goal of rapidly translating personalized cancer medicine into standards for clinical care. The members share information and conduct multi-institutional, global clinical trials, and research to discover and validate advances in genomic and biomarker-based cancer medicine.

In a statement, Asan Cancer Centre Director Chang Sik Yu said that membership into the consortium "will provide us with the opportunity to promote ground-breaking global clinical trials with other leading organizations to advance personalized cancer medicine. With this opportunity, we hope to make an important contribution to this worldwide effort to overcome cancer."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.